<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03891394</url>
  </required_header>
  <id_info>
    <org_study_id>ainshamHE4</org_study_id>
    <nct_id>NCT03891394</nct_id>
  </id_info>
  <brief_title>Human Epididymis Protein 4 in Women With Severe Preeclampsia / HELLP Syndrome</brief_title>
  <official_title>Prognostic Value of Human Epididymis Protein 4 (HE4) for Persistent Proteinuria in Women With Severe Preeclampsia / HELLP Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pre-eclampsia seems to be associated with a four to five times increase risk of later
      microalbuminuria and CKD which might suggest a possible direct renal damage from
      pre-eclampsia
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2019</start_date>
  <completion_date type="Anticipated">October 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>protein in urine</measure>
    <time_frame>12 weeks postpartum</time_frame>
    <description>proteinuria &gt; 0.3 mg protein / mg creatinine.</description>
  </primary_outcome>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Preeclampsia</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Human epididymis protein 4</intervention_name>
    <description>Human epididymis protein 4 serum level in predicting persistent proteniuria</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The diagnosis is made after 20 weeks of gestation in previously normotensive women who
        develop:

          -  Systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥110 mmHg and
             proteinuria (with or without signs and symptoms of significant end-organ dysfunction).

          -  Systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg (with or
             without proteinuria) and one or more of the following signs and symptoms of
             significant end-organ dysfunction
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pregnant women 18-35 years old.

          2. Fulfilling the criteria for diagnosis of sever preeclampsia.

          3. Fulfilling the criteria for diagnosis of HELLP syndrome

        Exclusion Criteria:

          1. Diabetes mellitus

          2. Preexisting renal disease.

          3. Chronic hypertension

          4. Rheumatologic diseases

          5. Adnexal mass.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
  </eligibility>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 25, 2019</study_first_submitted>
  <study_first_submitted_qc>March 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2019</study_first_posted>
  <last_update_submitted>March 27, 2019</last_update_submitted>
  <last_update_submitted_qc>March 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Radwa Rasheedy Ali</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>HELLP Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

